Cargando…
Real life rates of sustained virological response (SVR) and predictors of relapse following DAA treatment in genotype 3 (GT3) patients with advanced fibrosis/cirrhosis
BACKGROUND: Treatment of GT3 remains challenging compared to other genotypes. AIMS: To explore real life SVR rates and to identify predictors of virological failure across the most recently used Direct acting antiviral (DAA) regimens in a large cohort of Italian patients with cirrhosis or advanced f...
Autores principales: | Mangia, Alessandra, Losappio, Ruggero, Cenderello, Giovanni, Potenza, Domenico, Mazzola, Michele, De Stefano, Giulio, Terreni, Natalia, Copetti, Massimiliano, Minerva, Nicola, Piazzola, Valeria, Bacca, Donato, Palmieri, Vincenzo, Sogari, Fernando, Santoro, Rosanna |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6067691/ https://www.ncbi.nlm.nih.gov/pubmed/30063745 http://dx.doi.org/10.1371/journal.pone.0200568 |
Ejemplares similares
-
SVR12 Higher than 97% in GT3 Cirrhotic Patients with Evidence of Portal Hypertension Treated with SOF/VEL without Ribavirin: A Nation-Wide Cohort Study
por: Mangia, Alessandra, et al.
Publicado: (2019) -
SVR12 rates higher than 99% after sofosbuvir/velpatasvir combination in HCV infected patients with F0-F1 fibrosis stage: A real world experience
por: Mangia, Alessandra, et al.
Publicado: (2019) -
Correction: SVR12 rates higher than 99% after sofosbuvir/velpatasvir combination in HCV infected patients with F0-F1 fibrosis stage: A real world experience
por: Mangia, Alessandra, et al.
Publicado: (2019) -
Dynamics of APRI and FIB-4 in HCV cirrhotic patients who achieved SVR after DAA therapy
por: Leuştean, Anca, et al.
Publicado: (2021) -
Treatment of hepatitis C virus genotype 4 in the DAA era
por: Di Biagio, Antonio, et al.
Publicado: (2018)